MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-05-2026
EyePoint Pharmaceuticals DIO Ratio 2011-2026 | EYPT
Annual DIO Ratio EyePoint Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 334 | 290 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 334 | 290 | 312 |
Quarterly DIO Ratio EyePoint Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 402 | - | - | - | 335 | 212 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 276 | 334 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 402 | 212 | 312 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B |  USA |
 |
Esperion Therapeutics
ESPR
|
2.46 K | $ 3.13 | 0.39 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
96.1 | $ 45.86 | 3.23 % | $ 12.5 B | USA |
 |
Fortress Biotech
FBIO
|
210 | $ 2.51 | 2.03 % | $ 70 M | USA |
 |
Galapagos NV
GLPG
|
0.915 | $ 28.95 | 1.97 % | $ 2.69 B |  Belgium |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.37 | 1.2 % | $ 6.83 B |  Spain |
 |
Immuron Limited
IMRN
|
1.32 K | $ 0.81 | 2.15 % | $ 6.7 M |  Australia |
 |
Ionis Pharmaceuticals
IONS
|
259 | $ 76.26 | 1.34 % | $ 12.2 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
Kamada Ltd.
KMDA
|
166 | $ 8.25 | 0.49 % | $ 260 M |  Israel |
 |
ACADIA Pharmaceuticals
ACAD
|
295 | $ 22.93 | 2.6 % | $ 3.8 B | USA |
 |
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M |  Canada |
 |
MannKind Corporation
MNKD
|
430 | $ 4.01 | 40.03 % | $ 1.23 B | USA |
 |
Albireo Pharma
ALBO
|
26.1 | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
185 | $ 23.48 | 0.26 % | $ 2.99 B | USA |